KBC Group
DNLI icon

KBC Group’s Denali Therapeutics DNLI Stock Holding History

KBC Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$127K Hold
4,943
– – ﹤0.01% 1273
2026
Q1 		$95K Sell
4,943
-1,325
-21% -$26.4K ﹤0.01% 1346
2025
Q4 		$103K Buy
6,268
+1,773
+39% +$29.9K ﹤0.01% 1251
2025
Q3 		$65K Hold
4,495
– – ﹤0.01% 1533
2025
Q2 		$63K Sell
4,495
-1,955
-30% -$27.5K ﹤0.01% 1476
2025
Q1 		$88K Buy
6,450
+116
+2% +$2.22K ﹤0.01% 1551
2024
Q4 		$129K Buy
6,334
+2,731
+76% +$69.9K ﹤0.01% 1382
2024
Q3 		$105K Hold
3,603
– – ﹤0.01% 1251
2024
Q2 		$84K Buy
3,603
+1,138
+46% +$21.8K ﹤0.01% 1272
2024
Q1 		$51K Hold
2,465
– – ﹤0.01% 1546
2023
Q4 		$53K Hold
2,465
– – ﹤0.01% 1482
2023
Q3 		$51K Buy
+2,465
New +$62.5K ﹤0.01% 1428

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KBC Group's DNLI Position: Q2 2026 in Review

KBC Group held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 4,943 shares worth $127K. The position accounts for ﹤0.01% of the portfolio, ranked #1273.

KBC Group first reported a position in DNLI in Q3 2023 and has held it in 12 quarters since. The position peaked at $129K in Q4 2024. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • KBC Group held 4,943 shares of Denali Therapeutics worth $127K as of Q2 2026.
  • KBC Group left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1273 holding.
  • KBC Group first reported a position in Denali Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • KBC Group's Denali Therapeutics position peaked at $129K in Q4 2024.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.